Platelet-derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization

Mohammad Ali Sadiq, Mostafa Hanout, Salman Sarwar, Muhammad Hassan, Aniruddha Agarwal, Yasir Jamal Sepah, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Retinochoroidal vascular diseases are the leading causes of blindness in the developed world. They include diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration (AMD), and pathological myopia, among many others. Several different therapies are currently under consideration for the aforementioned disorders. In the following section, agents targeting platelet-derived growth factors (PDGF) are discussed as a potential therapeutic option for retinochoroidal vascular diseases. PDGF play an important role in the angiogenesis cascade that is activated in retinochoroidal vascular diseases. The mechanism of action, side effects, efficacy, and the potential synergistic role of these agents in combination with other treatment options is discussed. The future of treatment of retinochoroidal vascular diseases, particularly neovascular AMD, has become more exciting due to agents like PDGF antagonists.

Original languageEnglish (US)
Pages (from-to)310-316
Number of pages7
JournalDevelopments in Ophthalmology
StatePublished - 2015

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Platelet-derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization'. Together they form a unique fingerprint.

Cite this